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Abstract
Background—Antiretroviral (ARV) management in pediatrics is a challenging process in which 
multiple barriers to optimal therapy can lead to poor clinical outcomes. In a pediatric HIV clinic, 
we implemented a systematic ARV stewardship program to evaluate ARV regimens and make 
recommendations for optimization when indicated.
Methods—A comprehensive assessment tool was used to screen for issues related to genotypic 
resistance, virologic/immunologic response, drug-drug interactions, side effects, and potential for 
regimen simplification. The ARV stewardship team (AST) made recommendations to the HIV 
clinic provider, and followed patients prospectively to assess clinical outcomes at 6 and 12 months.
Results—The most common interventions made by the AST included regimen optimization in 
patients on suboptimal regimens based on resistance mutations (35.4%), switching to safer ARVs 
(33.3%), and averting significant drug-drug interactions (10.4%). In patients anticipated to have a 
change in viral load (VL) as a result of the AST recommendations, we identified a significant 
benefit in virologic outcomes at 6 and 12 months when recommendations were implemented 
within 6 months of ARV review. Patients who had recommendations implemented within 6 
months had a 7-fold higher probability of achieving a 0.7 log10 reduction in VL by 6 months, and 
this benefit remained significant after controlling for adherence [adjusted OR 6.8 (95% CI 
1.03-44.9, p <0.05)].
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Conclusions—A systematic ARV stewardship program implemented at a pediatric HIV clinic 
significantly improved clinical outcomes. ARV stewardship programs can be considered a core 
strategy for continuous quality improvement in the management of HIV-infected children and 
adolescents.
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Introduction
Management of combination antiretroviral therapy (cART) in pediatric patients infected with 
human immunodeficiency virus (HIV) is a challenging process in which providers need to 
consider the therapeutic goals of CD4 gains and viral load (VL) suppression along with the 
complications associated with long-term therapy such as toxicities and accumulation of 
resistance associated mutations (RAMs)1. For infants and young children with perinatally-
acquired HIV, the limited availability of suitable drug formulations and lack of dosing 
recommendations for newer agents can limit the use of more potent and better-tolerated 
antiretrovirals (ARVs). For adolescents, multiple cognitive, mental health, and psychosocial 
factors such as lack of family support and risk-taking behaviors can serve as barriers to 
medication adherence, which can lead to virologic failure2-4.
Medication errors such as drug omissions, dosing errors, and major drug-drug interactions, 
occur in up to 86% of HIV-infected inpatients5,6,7. Antimicrobial stewardship programs 
(ASPs) have been advocated to optimize antimicrobial selection, dosing, route, and duration 
of therapy to maximize clinical cure while limiting unintended consequences, such as 
emergence of resistance, adverse drug events, and cost8. The same core strategies 
recommended for ASPs could be applied to optimize therapy in HIV-infected individuals. 
Several studies have investigated the role of various interventions on reducing medication 
errors in hospitalized HIV-infected patients7,9-18, as well as in the outpatient HIV clinic 
setting19-25. However, few studies assessed the appropriateness of ARV regimens based on 
resistance testing21,24, and few evaluated clinical outcomes such as CD4 gains and VL 
suppression21,22,24. Furthermore, no studies have been conducted in the pediatric HIV 
population.
As pediatric patients grow into adults and as newer drugs and pediatric formulations become 
available, there is a need for continuous optimization and simplification of ARV regimens. 
In July 2010, an ARV stewardship quality improvement (QI) program was implemented at 
our outpatient pediatric HIV clinic to systematically review and evaluate medication 
regimens prescribed to our patients. ARV-related issues identified were discussed with the 
patients’ HIV clinic provider, and the ARV stewardship team (AST) made recommendations 
for therapy optimization. The purpose of this prospective observational study was to (1) 
characterize the ARV-related issues identified and types of interventions recommended by 
the AST, (2) determine the proportion of interventions implemented by the HIV clinic 
provider, and (3) evaluate clinical outcomes at 6 and 12 months after initial review by the 
AST.
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Methods
Study design and patient selection
Starting July 2010, a pediatric infectious diseases physician and pediatric infectious diseases 
clinical pharmacist, both with specialized HIV training, systematically reviewed patients 
followed at the outpatient Intensive Primary Care (IPC) Clinic at The Johns Hopkins 
Hospital. The IPC clinic providers consisted of pediatric infectious diseases trained 
physicians, adolescent medicine trained physicians, and nurse practitioners, with an average 
of 13 years of experience (range 5-25 years) managing HIV-infected children and 
adolescents. Patients were screened using a comprehensive assessment tool (Figure 1), 
which screened for issues related to (1) regimen appropriateness based on cumulative 
genotypic resistance profiles and ARV exposure history, (2) virologic and immunologic 
response, (3) drug-drug interactions, (4) short and long-term adverse effects, and (5) 
potential for regimen simplification to enhance adherence. ARV-related issues identified and 
recommendations for changes were discussed at the weekly multidisciplinary IPC clinic 
meeting with the patients’ HIV clinic provider, and it was at the discretion of the clinic 
provider whether or not recommendations would be implemented. This QI study was 
reviewed and approved by the Institutional Review Board at The Johns Hopkins Hospital 
with a waiver of informed consent.
Data collection
Baseline demographic and clinical characteristics were collected from electronic medical 
records on the date of review by the AST, and patients were prospectively followed to assess 
whether or not interventions recommended were implemented and time to implementation 
was calculated. Clinical outcomes relevant to the intervention recommended were also 
prospectively assessed from the electronic medical records (e.g. CD4/VL change, resolution 
of side effect, resolution of drug-drug interaction). For interventions in which a change in 
CD4 and/or VL was anticipated as a result of the recommendations made by the AST, 
change in CD4 count and VL at 6 and 12 months was calculated from the time of ARV 
review.
Definitions
Baseline adherence was defined as adherent vs. not by the HIV clinic provider when patients 
were discussed at our multidisciplinary clinic meeting. Adherence determination was made 
by mechanisms that included but were not limited to the following: patient/caregiver 
admission of incomplete adherence, persistent viremia despite reported adherence to the 
drug regimen and without other plausible explanation (e.g., drug interactions), pill counts 
inconsistent with reported pill intake (if applicable), pharmacy prescription refill history 
consistent with incomplete adherence (if available), drug levels (if measured), and 
knowledge of the social situation/family dynamics. Previous ARV exposure was defined as 
“treatment experienced” if the patient had been exposed to less than 2 previous cART 
regimens, and “extensively treatment experienced” if the patient had been exposed to 2 or 
more previous cART regimens. All available genotypes were reviewed to compile a 
cumulative genotype for each patient. Patients’ prior ARV exposure was also taken into 
account when considering possible resistance. For example, in patients with extensive 
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nucleoside reverse transcriptase inhibitor (NRTI) exposure with multiple thymidine analogue 
mutations (TAMs), an M184V was inferred even if it did not appear on the patients’ 
genotypes. Genotypic resistance was assessed according to the most updated International 
AIDS Society (IAS) resistance mutations list26-29 that was available at the time of ARV 
review, and ARV regimens were considered “suboptimal” if the overall summative activity 
was less than 2 fully active agents (i.e. regimens could have had multiple partially active 
agents that, taken together, were the equivalent of a regimen containing less than 2 fully 
active agents). Regimen optimization was defined as a recommendation that would change 
the patients’ cART regimen from <2 fully active agents to at least 2 fully active agents from 
2 different classes.
Outcomes
The primary outcomes of interest included the median change in CD4 count and VL, and 
proportion of patients achieving a decline in VL of at least 0.7 log10 at 6 and 12 months after 
ARV review. These outcomes were assessed in patients in whom a change in CD4 and/or VL 
was anticipated as a result of the recommendations made by the AST. Outcomes were 
compared between those with recommendations implemented within 6 months of ARV 
review vs. those in which recommendations were not implemented within 6 months. 
Secondary outcomes of interest included resolution of side effects and drug-drug 
interactions.
Statistical analysis
Patient demographic and clinical characteristics were summarized using descriptive statistics 
(median and interquartile range (IQR), frequencies and percentages). Comparisons were 
made using chi-squared (χ2) test for categorical data and Wilcoxon rank sum test for 
continuous data. Logistic regression analyses were used to estimate odds ratios (ORs) and 
95% confidence intervals (CIs) for the outcome of achieving a decline in VL of at least 0.7 
log10 by 6 and 12 months after ARV review. All analyses were performed using STATA 
statistical software version 13.1 (StataCorp LP., College Station, TX); a 2-sided P value < 
0.05 was used to determine statistical significance.
Results
The AST reviewed 106 of 198 (54%) IPC clinic patients between July 2010 and March 2014 
(Figure 2). ARV-related issues were identified in 48 of 106 (45%) patients reviewed. When 
patients with identified ARV-related issues (n=48) were compared to those without (n=58), 
patients with identified ARV-related issues tended to be younger (median (IQR) age 18.5 
(10.5-21) vs. 20 (16-21.5) years, p 0.08), perinatally-infected (95.8% vs. 75.9%, p < 0.01), 
and had lower baseline CD4 counts (median (IQR) 523.5 (340-897.5) vs. 672.5 (444-776) 
cells/mm3, p 0.16). Baseline demographics and clinical characteristics of the 48 patients 
with identified ARV-related issues are shown in Table 1. 72.9% of patients were extensively 
treatment experienced, 75% had reverse transcriptase (RT) RAMs, and 58.3% had protease 
(PR) RAMs. The most common cART regimen prescribed at the time of ARV review was 
lopinavir/ritonavir plus 2 NRTIs. 47.9% of patients were determined by their providers to be 
non-adherent.
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The most commonly identified ARV-related issues included suboptimal regimen based on 
RAMs at baseline (35.4%), stavudine-containing regimens (18.8%), lopinavir/ritonavir or 
fosamprenavir-containing regimens (14.6%), and significant drug-drug interactions (10.4%) 
(Table 2). The most common types of interventions recommended by the AST included 
regimen optimization in patients on suboptimal regimens based on resistance mutations 
(35.4%), switching to safer ARVs (33.3%), and averting significant drug-drug interactions 
(10.4%). The rates of implementation in each category of intervention are summarized in 
Table 2. By July 1, 2014, 35 of 48 (73%) recommendations made by the AST were 
implemented, and 21 of these 35 (60%) were implemented within 6 months of ARV review 
(Figure 2). The median (IQR) time to implementation of recommendations was 134 
(28-322) days.
Outcomes
The primary outcome of change in CD4 count and VL by 6 and 12 months was assessed in 
28 patients in whom a change in CD4 and/or VL was anticipated as a result of the 
recommendations made by the AST. There were 10 patients included in the primary 
outcomes analysis who had recommendations implemented within 6 months of ARV review, 
and 18 patients included who did not have recommendations implemented within 6 months 
(Figure 2). There were no differences between the two groups with respect to age, HIV 
acquisition, previous ARV exposure, baseline CD4 count, baseline VL, presence of RT or 
PR RAMs, or baseline adherence (data not shown).
At 6 months, there was no significant difference in change in CD4 count between those with 
recommendations implemented within 6 months vs. not [median (IQR) change was 59.5 
(−22 to 185) vs. −15 (−84 to 166.5) cells/mm3, p 0.47] (Figure 3). By 12 months, there was 
a trend towards better CD4 improvements if recommendations were implemented within 6 
months [268.5 (11 to 401) vs. 0 (−39 to 64) cells/mm3, respectively, p 0.14].
For median change in VL (log10), there was a significant benefit seen at 6 months in those 
with recommendations implemented by 6 months [−1.32 (−2 to 0) vs. 0.12 (−0.56 to 0.64) 
log10, respectively, p 0.02]. Similarly at 12 months, there was a significant benefit seen in 
median change in VL (log10) in those with recommendations implemented by 6 months 
[−1.3 (−2 to −1) vs. 0 (−0.11 to 0.21) log10, respectively, p 0.01]. Additionally, higher 
proportions of patients with recommendations implemented by 6 months achieved a change 
in VL of at least −0.7 log10 at 6 and 12 months after ARV review (70% vs. 25%, 
respectively, at 6 months (p 0.04), and 83.3% vs. 7.14%, respectively, at 12 months (p = 
0.001).
The odds of achieving the outcome of change in VL of at least −0.7 log10 at 6 months was 
an unadjusted OR of 7 (95% CI 1.07 to 45.9, p 0.043) when recommendations were 
implemented by 6 months. After adjusting for baseline adherence, the adjusted OR at 6 
months was 6.8 (95% CI 1.03 to 44.9, p <0.05). The unadjusted OR of achieving a change in 
VL of at least −0.7 log10 at 12 months was 65 (95% CI 3.38 to 1251, p 0.006) when 
recommendations were implemented by 6 months. Due to the small sample size, an adjusted 
OR at 12 months could not be calculated.
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In terms of secondary outcomes, amongst patients with actual side effects due to ARVs 
(n=3), 2 had hypercholesterolemia on lopinavir/ritonavir, both were switched to the more 
lipid friendly boosted atazanavir, and both had decreases in lipids at 6 and 12 months after 
the switch. One patient had facial lipoatrophy on stavudine, which was switched to a safer 
NRTI, and no further progression of lipoatrophy was observed at 6 and 12 months. Five 
patients had significant drug-drug interactions including various acid suppressants with 
atazanavir, tenofovir with unboosted atazanavir, and fluticasone with PIs. All five patients 
had regimen changes implemented that averted the interaction.
Discussion
This is the first study to our knowledge that demonstrates that an ARV stewardship program 
implemented in an outpatient pediatric HIV clinic can improve clinical outcomes. We 
identified a significant benefit in virologic outcomes at 6 and 12 months when 
recommendations were implemented within 6 months of ARV review. Patients who had 
recommendations implemented within 6 months had a 7-fold higher probability of achieving 
a 0.7 log10 reduction in VL by 6 months, and this benefit remained significant after 
controlling for adherence. Our findings demonstrate that even in a highly specialized 
pediatric HIV clinic with experienced prescribers, suboptimal regimens and medication 
errors can still occur contributing to loss of virologic control, and the implementation of a 
systematic ARV stewardship program resulted in significantly improved clinical outcomes.
Previous studies conducted in adult HIV-infected inpatients have demonstrated that 
medication reconciliation and profile review conducted by an HIV or infectious diseases 
trained pharmacist can significantly reduce medication errors9-18. In the adult outpatient 
HIV clinic setting, many studies have demonstrated positive outcomes of various 
interventions19-25, some included interventions involving assessment of appropriateness of 
ARV regimens based on resistance testing21,24, and some have demonstrated improvement 
in CD4 gains and VL suppression21,22,24. In our study conducted in the pediatric population, 
the majority of interventions made by the AST were related to regimen optimization due to 
genotypic resistance, switching to safer ARVs, and averting significant drug-drug 
interactions. Similar to adult studies, we demonstrated that the implementation of our 
systematic AST had a positive impact on clinical outcomes, particularly VL reduction.
In our study, the implementation rate of recommendations made by the AST was 73%, 
which is lower compared to previous studies in adults where 100% of recommendations 
were implemented21,24. Only 60% of recommendations implemented were within 6 months 
of ARV review. The median time to implementation was ~4.5 months, which was longer 
than desired especially for recommendations that involved regimen optimization. From 
discussions at our weekly multidisciplinary meeting, we learned that a significant barrier to 
regimen optimization is the concern for preservation of future treatment options in a non-
adherent population that has decades of cART ahead of them. In patients who are 
intermittently adherent, providers may defer regimen optimization while attempting to 
resolve adherence issues, which is regarded as an acceptable but not ideal interim strategy30. 
Oftentimes, therapy optimization requires complex regimens with increased pill burden that 
could further jeopardize adherence resulting in virologic failure, emergence of RAMs on the 
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new regimen, and the inability to preserve drugs for future use. However, maintaining 
patients on failing regimens is not desirable as this may also increase the risk of selecting 
more RAMs, jeopardizing future treatment options. Therefore, the potential to initiate 
optimal therapy should be reassessed at every opportunity30.
Currently, there are no consensus guidelines for the implementation of ARV stewardship 
programs. The Infectious Diseases Society of America guidelines for antimicrobial 
stewardship8 do not discuss the role of stewardship programs in the HIV population, and the 
Department of Health and Human Services guidelines for the management of HIV in 
pediatric30 and adolescent31 populations do not mention stewardship or other means of QI as 
a strategy to improve clinical outcomes of patients infected with HIV. Our study, and 
previous studies21,24 have shown that outpatient ARV stewardship programs can positively 
impact clinical outcomes. Therefore, we believe that ARV stewardship programs have 
significant value in this difficult to manage population where considerations for drug-drug 
interactions, dose adjustments, emergence of resistance, co-morbid conditions, significant 
toxicities, etc. make therapy selection challenging, particularly as our armamentarium of 
agents is a constantly expanding. Even in highly specialized HIV clinics such as our own, 
there was still room for improvement as ARV-related issues were identified in almost half of 
patients reviewed by the AST. We believe that our systematic approach to assessment, as 
outlined in Figure 1, can be applied in any clinical setting when evaluating appropriateness 
of cART in an HIV-infected patient.
There are limitations to our study, notably the small number of patients included in our 
primary outcomes analysis of change in CD4 and VL, which significantly limits our power 
to detect differences in outcomes. Another limitation is the high rate of non-adherence 
(~50%), however this rate is consistent with what is reported in the literature on non-
adherence in the adolescent HIV-infected population in North America32. Additionally, our 
definition of non-adherence was categorical (yes or no) based on providers’ judgment, and 
not objectively measured in a systematic quantitative fashion. Although we controlled for 
adherence in our final model, baseline non-adherence could have biased providers to not 
implement recommendations made by the AST. Other limitations include the fact that this 
was a single center study, and although we believe that our systematic approach to cART 
assessment can be applied to any clinical setting, our results may not be generalizable to 
other clinic settings where resources for continuous systematic review may not be available, 
or the expertise of an HIV-trained pharmacist and/or physician is not available.
Measurement of quality of care and implementation of continuous QI programs to address 
gaps in care is advocated to improve clinical outcomes and successful therapy in HIV-
infected individuals33. Previous publications of QI programs in outpatient HIV clinics have 
evaluated quality of care indicators such as achievement of VL suppression and shown that 
the implementation of a QI program has the potential to increase the proportion of patients 
achieving VL suppression34. Future steps for our ARV stewardship program will include 
identifying key quality measures to track longitudinally, and set goals for achievement for 
selected measures.
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In conclusion, ARV stewardship is an effective strategy to improve clinical outcomes in 
pediatric patients infected with HIV, resulting in significant reductions in VL at 6 and 12 
months when recommendations made by the AST were implemented within 6 months of 
review. In patients who are virologically suppressed, switching to safer and better-tolerated 
ARVs with fewer long-term side effects is also an important goal. In this heavily pre-treated 
cohort of pediatric patients harboring significant RAMs, there are many potential barriers to 
the achievement of VL suppression including non-adherence, ARV dosing/formulation 
availability, drug-drug interactions, side effects, and the need to preserve future treatment 
options. ARV stewardship is able to modify or attenuate many of these barriers, leading to 
improved clinical outcomes, and should be considered as a core strategy for continuous QI 
in the management of HIV-infected children and adolescents.
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Figure 1. 
Antiretroviral stewardship assessment tool
NOTE: ARV = antiretroviral, VL = viral load, IPC = intensive primary care, PI = protease 
inhibitor
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Figure 2. 
Selection of patients for study inclusion
* Included patients in whom a change in CD4 and/or VL was anticipated as a result of the 
recommendations made by the ARV stewardship team
NOTE: ARV = antiretroviral, VL = viral load, IPC = intensive primary care
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Figure 3. 
Change in CD4 count (Panel A) and viral load (Panel B) at 6 and 12 months post-
antiretroviral review for 28 patients in which improvement in CD4 count and/or viral load 
was anticipated as a result of the recommendations made by the antiretroviral stewardship 
team
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Table 1
Baseline demographic and clinical characteristics of 48 patients with identified antiretroviral-related issues
Baseline characteristics Result
Age at time of ARV review (years), median (IQR) 18.5 (10.5-21)
Gender, n (%)
    Female 30 (62.5)
    Male 18 (37.5)
Race, n (%)
    African-American 40 (83.3)
    White 5 (10.4)
    Mixed/Other 3 (6.3)
HIV acquisition, n (%)
    Perinatal 46 (95.8)
    Non-perinatal 2 (4.2)
Previous ARV exposure*, n (%)
    Extensively treatment experienced 35 (72.9)
    Treatment experienced 13 (27.1)
CD4 (cells/mm3), median (IQR) 523.5 (340-897.5)
CD4 nadir (cells/mm3), median (IQR) 245 (18.5-548.5)
Viral load (log10), median (IQR) 2.1 (1.69-3.88)
Any reverse transcriptase resistance mutations at baseline, n (%) 36 (75)
Any protease resistance mutations at baseline, n (%) 28 (58.3)
cART prescribed at time of review, n (%)
    Lopinavir/ritonavir plus 2 NRTIs 19 (39.6)
    Atazanavir +/− ritonavir plus 2 NRTIs 13 (27)
    NNRTI plus 2 NRTIs 6 (12.5)
    NNRTI plus PI plus NRTI 3 (6.3)
    Darunavir/ritonavir containing regimen 2 (4.2)
    Other^ 5 (10.4)
Adherence to currently prescribed cART, n (%)
    Yes 25 (52.1)
    No 23 (47.9)
NOTE: ARV = antiretroviral, cART = combination antiretroviral therapy, IQR = interquartile range, NNRTI = non-nucleoside reverse transcriptase 
inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor
*
Previous ARV exposure was defined as “treatment experienced” if the patient had been exposed to less than 2 previous cART regimens, and 
“extensively treatment experienced” if the patient had been exposed to 2 or more previous cART regimens.
^
Includes: dual boosted PIs plus 2 NRTIs (n=1), lopinavir/ritonavir plus 3 NRTIs (n=1), nelfinavir plus 2 NRTIs (n=1), enfuvirtide plus PI plus 2 
NRTIs (n=1), unboosted fosamprenavir plus 2 NRTIs (n=1)
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Table 2
Summary of identified antiretroviral-related issues, types of interventions recommended by antiretroviral 
stewardship team, and frequency of implementation
Identified ARV-related issues (n=48) Type of intervention recommended Proportion of 
interventions 
implemented in 
each category, n (%)
Suboptimal regimen based on resistance mutations at baseline (n=17) Regimen optimization 12 (70.6)
Stavudine-containing regimen (n=8) Switch to safer NRTI 5 (62.5)
Lopinavir/ritonavir or fosamprenavir containing-regimen* (n=5) Switch to safer PI 3 (60)
Significant drug-drug interaction^ (n=5) Alternative regimen to avoid drug-drug interaction
5 (100)
Regimen simplification (n=4) Regimen simplification 2 (50)
Hypercholesterolemia on lopinavir/ritonavir (n=2) Switch to more lipid friendly PI 2 (100)
Dual-boosted PI-based regimen (n=1) Regimen optimization 1 (100)
Concern for potential non-adherence on NNRTI-based regimen (n=1) Switch from NNRTI to PI-based regimen 1 (100)
Concern for lack of CD4 gains despite virologic suppression (n=1) Continue current regimen 1 (100)
Concern for facial atrophy on stavudine (n=1) Switch from stavudine to safer NRTI 1 (100)
Switch from pill to liquid (n=1) Switch from pills to liquid 1 (100)
Switch from once daily to twice daily based on patient's preference 
(n=1)
Regimen optimization 1 (100)
Wrong dose of ARV prescribed (n=1) Change in dose of ARV 0 (0)
NOTE: ARV = antiretroviral, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, PI = 
protease inhibitor
*
Patients on lopinavir/ritonavir or fosamprenavir containing regimens were between the ages of 9 and 22 years, and could have been switched to 
newer, safer PIs
^
Included various acid suppressants with atazanavir, tenofovir with unboosted atazanavir, and inhaled corticosteroids (fluticasone) with PIs
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